Mölndal, Sweden and Cambridge, UK – 8th September 2016
Cellectricon AB, a leading provider of advanced cell-based discovery screening services, today announced a commercial collaboration with UK-based stem cell technology company Censo Biotechnologies Ltd. Under the agreement, the parties will provide a suite of high-quality Human iPSC based discovery services to support both preclinical neuroscience and chronic pain research.
“Through our collaboration with Censo, we are able to significantly enhance our discovery services offering for CNS and pain research”, said Cellectricon’s CEO David Burns. “Censo’s extensive stem cell knowledge complements our current expertise and screening service offering in the field of neuroscience. This collaboration provides the opportunity to meet industry’s demands for drug discovery models that are closer, and therefore more relevant, to humans.
Censo’s CEO Aidan Courtney added: “Censo is committed to the use of ethically approved Human iPSCs and their derivatives to advance drug discovery. There is an excellent alignment between Censo and Cellectricon and we are very excited about this collaboration. With our extensive expertise, we can provide important stem cell knowledge that adds further value to Cellectricon’s proprietary discovery services”.
About Censo Biotechnologies (www.censobio.com):
Censo Biotechnologies Ltd is a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. The company has the capabilities to generate induced pluripotent stem cells (iPSCs) from large cohorts of individuals and use the potential of these cells to create virtually any cell in the human body. By developing cell-based models of disease using cells from a diverse range of tissue donors, the company supports the development of new, targeted treatments for disease. Its major focus is the generation of novel data on drug efficacy and drug response variation for a given population. The company was founded in 2016 through the merger of Roslin Cellab and Roslin Cell Sciences and has facilities in both Edinburgh and Cambridge, UK.